NGL Fine Chem Ltd

NGL Fine Chem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

NGL Fine Chem Ltd

₹ 1,138 -2.00%
30 May - close price
nglfinechem.com BSE: 524774 NSE: NGLFINE
About

Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.[1]

Key Points

Business Overview:[1][2]
NGLFCL primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are used in the animal healthcare industry.

Product Profile:[3][4]
It has ~39 APIs (37 Veterinary APIs, 2 Human APIs), ~4 Intermediates, and ~12 finished dosage forms, etc., in the categories of Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements

Website BSE NSE - BE
  • Market Cap ₹ 704 Cr.
  • Current Price ₹ 1,138
  • High / Low ₹ 2,778 / 957
  • Stock P/E 38.8
  • Book Value ₹ 453
  • Dividend Yield 0.15 %
  • ROCE 8.08 %
  • ROE 6.68 %
  • Face Value ₹ 5.00
Edit ratios

Pros

Cons

  • Stock is trading at 2.52 times its book value
  • Company has a low return on equity of 10.5% over last 3 years.
  • Earnings include an other income of Rs.9.76 Cr.
  • Dividend payout has been low at 2.73% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
78.21 63.58 64.95 69.80 74.17 69.11 79.44 84.81 95.61 88.03 91.41 86.83 93.02
68.22 63.47 60.20 62.37 62.30 61.51 66.31 73.86 83.01 81.72 80.79 83.27 89.11
Operating Profit 9.99 0.11 4.75 7.43 11.87 7.60 13.13 10.95 12.60 6.31 10.62 3.56 3.91
OPM % 12.77% 0.17% 7.31% 10.64% 16.00% 11.00% 16.53% 12.91% 13.18% 7.17% 11.62% 4.10% 4.20%
2.28 3.01 4.10 2.95 1.45 3.80 3.76 4.19 4.16 6.27 5.43 0.15 -0.79
Interest 0.37 0.50 0.12 0.26 0.32 0.24 0.36 0.28 0.46 0.44 0.32 0.69 0.95
Depreciation 1.88 1.96 2.02 2.00 1.92 2.00 2.02 2.07 2.06 2.14 2.30 2.21 2.53
Profit before tax 10.02 0.66 6.71 8.12 11.08 9.16 14.51 12.79 14.24 10.00 13.43 0.81 -0.36
Tax % 21.56% 24.24% 26.08% 25.00% 23.01% 14.74% 24.47% 30.41% 23.81% 21.80% 25.24% 3.70% 44.44%
7.86 0.51 4.96 6.09 8.53 7.81 10.97 8.90 10.85 7.83 10.04 0.78 -0.52
EPS in Rs 12.72 0.83 8.03 9.86 13.81 12.64 17.76 14.41 17.56 12.67 16.25 1.26 -0.84
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
79 88 96 100 114 153 152 258 319 275 329 359
68 73 74 74 92 121 129 181 253 246 284 334
Operating Profit 11 15 22 25 22 32 23 77 66 29 45 26
OPM % 14% 17% 23% 26% 19% 21% 15% 30% 21% 10% 14% 7%
-1 2 0 1 3 4 1 9 13 8 16 10
Interest 2 2 2 1 2 3 3 2 2 2 2 2
Depreciation 2 3 3 3 5 6 7 7 8 8 8 9
Profit before tax 7 13 18 23 18 28 14 76 69 27 51 24
Tax % 32% 35% 36% 35% 29% 27% 26% 27% 24% 24% 24% 24%
5 8 11 15 13 20 11 55 52 20 39 18
EPS in Rs 7.33 13.48 18.45 24.10 20.38 32.58 17.16 89.79 84.57 32.57 62.35 29.35
Dividend Payout % 0% 0% 0% 0% 0% 5% 10% 2% 2% 5% 3% 0%
Compounded Sales Growth
10 Years: 15%
5 Years: 19%
3 Years: 4%
TTM: 9%
Compounded Profit Growth
10 Years: 10%
5 Years: 8%
3 Years: -30%
TTM: -53%
Stock Price CAGR
10 Years: 26%
5 Years: 24%
3 Years: -15%
1 Year: -49%
Return on Equity
10 Years: 19%
5 Years: 18%
3 Years: 11%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 3 3 3 3 3 3 3 3 3 3 3 3
Reserves 21 30 41 56 69 89 98 152 203 222 260 277
17 13 14 23 27 27 28 16 30 32 34 72
15 21 19 20 31 23 26 34 41 30 56 74
Total Liabilities 56 67 78 102 129 142 156 206 278 288 353 426
19 17 24 25 56 61 61 58 59 59 60 120
CWIP 0 1 2 16 3 0 0 1 6 26 46 50
Investments 0 2 3 6 6 9 14 33 32 43 57 63
37 46 49 55 63 73 80 115 180 159 190 193
Total Assets 56 67 78 102 129 142 156 206 278 288 353 426

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-0 8 8 10 22 9 20 27 13 32 11 17
-4 -3 -10 -10 -21 -10 -19 -24 -13 -24 -17 -16
3 -4 2 0 0 0 -1 -1 -1 -1 -1 -1
Net Cash Flow -1 1 0 -0 1 -1 -0 2 -1 7 -7 0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 110 107 123 110 89 79 63 53 74 86 92 81
Inventory Days 77 106 90 114 134 106 154 132 133 69 99 97
Days Payable 105 150 122 139 187 92 114 94 84 59 110 107
Cash Conversion Cycle 82 63 91 85 35 93 103 91 124 97 82 71
Working Capital Days 88 77 96 85 54 107 98 78 116 104 106 159
ROCE % 24% 29% 37% 34% 22% 28% 15% 52% 35% 12% 19% 8%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
73.81% 73.81% 73.81% 73.53% 73.53% 73.06% 73.06% 72.74% 72.74% 72.74% 72.74% 72.74%
0.05% 0.05% 0.00% 0.00% 0.00% 0.02% 0.04% 0.10% 0.03% 0.02% 0.05% 0.00%
0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
26.14% 26.13% 26.19% 26.47% 26.46% 26.93% 26.91% 27.16% 27.24% 27.25% 27.23% 27.26%
No. of Shareholders 18,04218,50418,44018,28717,06617,62316,41015,04114,60814,57514,11014,386

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls